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Background. Invasive fungal diseases (IFD) caused by Cryptococcus and dimorphic fungi are associated with significant mor-
bidity and mortality. Isavuconazole (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed
for the treatment of IFD. It displays potent activity in vitro against these pathogens and in this report we examine outcomes of pa-
tients with cryptococcosis or dimorphic fungal infections treated with ISAV.
Methods. The VITAL study was an open-label nonrandomized phase 3 trial conducted to evaluate the efficacy and safety of
ISAV treatment in management of rare IFD. Patients received ISAV 200 mg 3 times daily for 2 days followed by 200 mg once-
daily (IV or PO). Proven IFD and overall response at end of treatment (EOT) were determined by an independent, data-review com-
mittee. Mortality and safety were also assessed.
Results. Thirty-eight patients received ISAV for IFD caused by Cryptococcus spp. (n = 9), Paracoccidioides spp. (n = 10), Cocci-
dioides spp. (n = 9), Histoplasma spp. (n = 7) and Blastomyces spp. (n = 3). The median length of therapy was 180 days (range 2–331
days). At EOT 24/38 (63%) patients exhibited a successful overall response. Furthermore, 8 of 38 (21%) had stable IFD at the end of
therapy without progression of disease, and 6 (16%) patients had progressive IFD despite this antifungal therapy. Thirty-three (87%)
patients experienced adverse events.
Conclusions. ISAV was well tolerated and demonstrated clinical activity against these endemic fungi with a safety profile similar
to that observed in larger studies, validating its broad-spectrum in vitro activity and suggesting it may be a valuable alternative to
currently available agents.
Clinical Trials Registration. NCT00634049.
Keywords. cryptococcosis; histoplasmosis; coccidioidomycosis; blastomycosis; paracoccidioidomycosis.
Cryptococcus and dimorphic fungi represent a diverse group of
fungal pathogens that share several characteristics including
their ability to infect otherwise healthy hosts but can also
cause severe infections in immunocompromised individuals.
Furthermore, residence within a specific environmental loca-
tion/niche allows exposure and development of disease [1]. In-
fection is typically acquired via inhalation of fungal spores or
conidia, and the spectrum of disease can range from
asymptomatic acquisition to life-threatening disseminated in-
fection [2, 3]. Current guidelines for the treatment of cryptococ-
cosis and dimorphic mycoses emphasize the primary role of
amphotericin B (AMB) formulations for induction therapy of
those with severe disease, while in contrast those with moderate
disease typically receive a triazole as initial therapy [4–8]. Inter-
patient pharmacokinetic variability with current agents, drug–
drug interactions, toxicity concerns, and in some cases lack of
efficacy [9], has led to the search for new agents in the treatment
of these invasive fungi. In this particular group of patients the
ability to use both parenteral and oral agents is clinically impor-
tant during management.
Isavuconazole (ISAV) is a novel triazole with a broad-spectrum
of antifungal activity administered as a water-soluble prodrug, isa-
vuconazonium sulfate. In vitro and animal studies have demon-
strated potential utility in the treatment of invasive aspergillosis
[10], mucormycosis [11], candidiasis [12], and certain endemic
mycoses [13, 14]. Both oral and intravenous formulations exist
as the prodrug isavuconazonium sulfate which undergoes cleavage
by plasma esterases to the active moiety ISAV. ISAV has been
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approved for use in the treatment of aspergillosis and mucormy-
cosis following the completion of phase 3 trials [15, 16]. Pharma-
cokinetics are facile because there is no demonstrable food effect
with oral administration [17], interpatient pharmacokinetic vari-
ability is minimal [18], and the intravenous prodrug formulation
does not require the addition of cyclodextrin to achieve solubility
and therefore can be used in patients with reduced renal function
[19].
We evaluated the results of a phase 3 study performed to de-
termine the safety and efficacy of ISAV as primary or salvage
therapy in the treatment of either cryptococcosis or dimorphic
mycoses.
METHODS
Study Design
VITAL (ClinicalTrials.gov, NCT00634049) was a phase 3, open-
label, nonrandomized trial conducted in 34 medical centers
worldwide that evaluated the efficacy, safety, and outcomes of
patients treated with ISAV for dimorphic fungi, emerging
molds and yeasts, or invasive aspergillosis in the setting of
renal impairment. Only patients infected with cryptococcosis
and dimorphic fungi are presented in this report.
Inclusion and Exclusion Criteria
All patients enrolled in this subset of the VITAL study had
proven infection with Cryptococcus or a dimorphic fungus by
EORTC/MSG criteria [20]. Eligibility criteria included age
≥18 years, weight ≥40 kg, rate-corrected QTc interval <500
ms, absence of severe liver injury, and no concurrent treatment
with strong inhibitors or inducers of cytochrome P450. Patients
who were intolerant or refractory to other antifungal agents
were also eligible for enrollment in this study. Primary therapy
was defined as the receipt of <4 days of other systemic antifun-
gal therapy within the 7 days preceding study enrollment. Dis-
semination was defined as any extrapulmonary infection (see
Supplementary Material).
Administration of Study Drugs
Patients received a loading regimen of ISAV 200 mg (adminis-
tered as isavuconazonium sulfate 372 mg) every 8 hours for 6
doses, followed by ISAV 200 mg once daily. Patients were treat-
ed orally or intravenously at the investigator’s discretion. Pa-
tients were evaluated daily for the first 3 days and, thereafter,
on treatment days 7, 14, 28, 42, and 84. If therapy was required
beyond day 84, patients were assessed monthly. Following dis-
continuation of ISAV, for any reason, patients underwent end of
therapy (EOT) assessment and 2 post-treatment monthly as-
sessments. At days 42, 84, and EOT, investigators documented
clinical, radiological, and mycological responses to therapy.
Study Oversight
The sponsors, Basilea Pharmaceutica International Ltd (Basel,
Switzerland) and Astellas Pharma Global Development, Inc.
(Northbrook, Illinois) designed the study protocol. Individual
site investigators and central laboratories provided all study
data. Study analysis was performed by the sponsors and they
vouch for the integrity and validity of all data. All authors
agreed to submit the manuscript for publication. The study
was conducted in accordance with the Declaration of Helsinki
(2000) and the International Conference on Harmonisation
Guidelines for Good Clinical Practice. The institutional review
board at each medical center approved the study. All patients
provided written informed consent prior to enrollment.
Efficacy and Safety Assessments
An independent data-review committee (DRC) verified the diag-
nostic certainty of all IFDs and provided a judgment for each as-
sessment component (clinical, radiological, and mycological
responses) and for the overall response for each patient. Overall
responses were classified as complete or partial responses (both
considered a treatment success), stable or progressive disease
(both considered treatment failure), based on these assessments
and following prespecified criteria (see Supplementary Materials).
The primary study endpoint was DRC-assessed overall re-
sponse at day 42. Prespecified secondary endpoints included as-
sessments of overall, clinical, radiological and mycological
responses at days 42, 84, and EOT, and all-cause mortality
through days 42 and 84 of ISAV treatment. The treatment of
the endemic mycoses and cryptococcosis is often prolonged
and for this reason efficacy at EOT was used for final outcome
assessments in this study.
Adverse events (AEs) and findings from the physical exami-
nation, laboratory tests, electrocardiograms, and imaging stud-
ies were recorded by the investigators at each study visit.
Laboratory procedures are outlined in the Supplementary
Materials. Patients had trough ISAV levels measured during
study visits. Fungal isolates from study participants underwent
central laboratory identification and susceptibility testing.
Antimicrobial Susceptibility Testing
All isolates were tested in accordance with the Clinical and Lab-
oratory Standards Institute M27-A3 methodology [21] at Case
Western Reserve University or the Fungus Testing Laboratory
(UT-San Antonio).
Plasma Isavuconazole Concentrations
Plasma levels of ISAV were measured on days 7, 14, 28, and pre-
sumed steady state (>day 30) 1 hour prior to the next scheduled
dose or 24 ± 1 hours after last dose. ISAV and the inactive cleav-
age product (prodrug moiety) concentrations in plasma samples
were measured using a validated liquid chromatography-mass
spectrometry/mass spectrometry (LC–MS/MS) method at Phar-
maceutical Product Development Inc., Middleton, Wisconsin.
Statistical Analysis
VITAL Study—patient characteristics, antifungal exposure, out-
comes, AEs, and mortality were summarized using descriptive
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statistics. Deaths were considered failures for all DRC
assessments.
RESULTS
A total of 149 patients were enrolled in the VITAL trial, of
which 38 were diagnosed with cryptococcosis or a dimorphic
mycosis. The patients (age, 20–79 years) were derived from
5 countries and 10 medical centers. Thirty-one of these 38 pa-
tients (81.6%) completed the study. Patients with specific my-
coses included 9 with cryptococcosis (C. neoformans, n = 4;
C. gattii, n = 3; Cryptococcus spp. not otherwise specified,
n = 2), 9 with coccidioidomycosis, 3 with blastomycosis, 7 with
histoplasmosis, and 10 paracoccidioidomycosis (Table 1). Most
patients received ISAV as primary therapy (33/38, 87%) for
these mycoses. The most common underlying conditions were
diabetes mellitus (n = 5) and chronic obstructive pulmonary dis-
ease (COPD) (n = 2).
Cryptococcosis
Most patients with cryptococcal infections received ISAV as pri-
mary therapy (6/9, 67%) (Table 2). Two patients received ISAV
following intolerance to alternative fungal therapy—in 1 patient
this followed 11 days of AMB therapy, in the other patient this
followed 17 days receiving combined AMB deoxycholate and
fluconazole. This latter patient had both disseminated nocar-
diosis and pulmonary cryptococcosis and died after only 6
days of ISAV treatment. The third patient not receiving ISAV
as primary therapy was clinically refractory to AMB deoxycho-
late and fluconazole after 16 days of therapy. The median
duration of ISAV therapy in these patients was 180 days
(range 6–182 days). Six patients with cryptococcosis had a
successful response (complete success in 2, partial success in
4), whereas stable disease was demonstrated in 2 other patients.
Of the 2 patients intolerant to prior therapy, one was a partial
responder to ISAV and the other exhibited progression of dis-
ease and was considered a failure. Eight of 9 patients survived
through EOT (all-cause mortality 1/9 [11%]).
Coccidioidomycosis
All patients with coccidioidomycosis received ISAV as primary
therapy for pulmonary infection (9/9, 100%); 1 patient had con-
comitant involvement of the pleura. All patients received ISAV
for a median of 180 days (range 180–183 days). At EOT, com-
plete or partial success was observed in 5/9 (56%) patients with
complete success in 2, including the patient with pleuropulmo-
nary disease. Those with partial success exhibited complete
clearance of infection radiographically (n = 2) and a solitary
pulmonary nodule (n = 1). The remaining 4/9 patients had sta-
ble disease at EOT. It is noteworthy that all 4 of these patients
had diabetes mellitus and all 4 exhibited persistent radiographic
abnormalities at EOT (fibrocavitary disease n = 2, and focal in-
filtrates n = 2). The DRC determined all 9 patients had a clinical
response to therapy at EOT.
Blastomycosis
Three patients were treated with blastomycosis, and 2 of these
received very short courses of therapy: 1 patient was intolerant
to itraconazole therapy in the treatment of pulmonary and gen-
itourinary blastomycosis and withdrew consent after 6 days of
ISAV although no adverse effects of therapy were noted, where-
as the other was treated with ISAV as primary therapy for blas-
tomycosis. In this second patient, dissemination was confirmed
(on day 2 of ISAV therapy) with lesions in the lung, spleen, and
skin; ISAV was subsequently discontinued and liposomal AMB
(L-AMB) initiated. This patient died on day 18 (following 16
days of L-AMB). A third patient with pulmonary blastomycosis
received ISAV after intolerance to itraconazole (anorexia) and
was treated for 331 days with a complete clinical and radio-
graphic response to therapy at EOT.
Histoplasmosis
Seven patients were treated for histoplasmosis. All received
ISAV as primary therapy – 3 with primary pulmonary infection
and 4 with dissemination including 1 with central nervous sys-
tem (CNS) involvement. Patients were treated for a median of
180 days (range 85–327 days). Complete clinical and radio-
graphic success was observed in the patient with CNS involve-
ment after 178 days of treatment. Partial success was found in 3
patients: 2 with disseminated disease, and 1 with lung disease
alone. Stable disease was documented in a heart transplant pa-
tient with isolated pulmonary infection, and progression (fail-
ure) was seen in 1 patient with dissemination and another with
Table 1. Response to Isavuconazole at the End of Treatment
Primary Diagnosis No. of Successful Outcomes at EOT (%)
Cryptococcosis
All types 6/9 (67)
Pulmonary 3/4 (75)
CNS 4/5 (80)
Non-CNS dissemination 0/1 (0)
Coccidioidomycosis
Pulmonary 5/9 (56)
Blastomycosis
All types 1/3 (33)
Pulmonary 1/1 (100)
Non-CNS dissemination 0/2 (0)
Histoplasmosis
All types 4/7 (57)
Pulmonary 3/5 (60)
CNS 1/1 (100)
Non-CNS dissemination 2/3 (66)
Paracoccidioidomycosis
All types 8/10 (80)
Pulmonary 6/8 (75)
CNS 0/1 (0)
Non-CNS dissemination 6/6 (100)
Abbreviations: CNS, central nervous system; EOT, end of treatment.
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lung disease despite 185 days of ISAV. All patients were alive at
EOT.
Paracoccidioidomycosis
All 10 patients with Paracoccidioides infections received ISAV as
primary therapy. Treatment was administered for a median of
180 days (range 27–182 days). Complete success was found in
1 patient with widespread dissemination after 180 days of treat-
ment, and partial success was determined in 7/10 (70%), with 5
of these 7 presenting with disseminated paracoccidioidomycosis
including 1 with AIDS (CD4 count = 144 cell/mm3). Progres-
sive disease was observed in 2 patients, both of whom died on
days 27 and 91 after starting ISAV.
Safety Results
Thirty-three (87%) patients experienced AEs. The most common
AEs were vomiting (n = 8), nausea (n = 6), back pain (n = 5), and
headache (n = 5). Twelve (32%) patients had a serious adverse
event (SAE) reported. Three events (septic shock, pneumonia,
and vomiting) were reported in 2 patients each. Other SAEs
were reported in a single patient. Fourteen (36.8%) patients had
a treatment-related AE (Table 3). No patients were discontinued
from the study primarily due to an AE.
In vitro Susceptibility Testing (MICs)
CLSI MIC data for ISAV were available for 22 isolates (Table 4):
Coccidioides, 0.06–0.12 µg/mL (n = 6); Cryptococcus gattii,
0.008–0.12 µg/mL (n = 7); C. neoformans, 0.008–1.2 µg/mL
(n = 6); Histoplasma, 0.03 µg/mL (n = 2); Paracoccidioides,
0.001 µg/mL (n = 1). Blastomyces isolates were not available
for susceptibility testing.
Plasma Isavuconazole Concentrations
On day 7 median levels were 3.2 µg/mL (range 0.61–5.05 µg/mL),
day 14 median levels were 3.86 µg/mL (range 0.88–5.98 µg/mL),
day 28 median levels were 4.01 µg/mL (range 0.78–7.80 µg/
mL), and assumed steady-state median levels were 4.05 µg/mL
(range 1.09–8.96 µg/mL).
DISCUSSION
This study demonstrates that ISAV has antifungal activity as both
primary and salvage therapy in patients with cryptococcosis and
dimorphic fungal infections. A successful response to therapy
Table 3. Number and Percentage of Patients With Treatment-related
Adverse Events
Adverse Eventa,b Total (N = 38) N (%)
Overall 14 (36.8)
Vomiting 3 (7.9)
Phlebitis 4 (10.5)
Diarrhea 2 (5.3)
Nausea 2 (5.3)
Chest pain 2 (5.3)
GGT elevation 2 (5.3)
Paresthesia 2 (5.3)
Somnolence 2 (5.3)
Alopecia, headache, dizziness, dyspepsia, abdominal pain, palpitations, xerosis, seizure,
insomnia, dyspnea, asthenia, epistaxis, injection site hemorrhage, injection site pain, back
pain, musculoskeletal pain, liver disorder, hepatomegaly, schistosomiasis, depression
each occurred once.
Abbreviation: GGT, gamma-glutamyl transferase.
a Patients may have experienced >1 of each type of treatment-related adverse event.
b No patients required treatment discontinuation or alteration due to adverse events.
Table 2. Treatment of Cryptococcosis
Patient Age Sex Comorbidity Site of Infection Species
Primary or Salvage
Therapy
Duration of
ISAV (days)
Mycologic
Response
Overall DRC
Assessment at EOT
1 45 M None Pulmonary NOS Primary therapy 180 Presumed
persistence
Stable Failure
2 43 M Polycythemia
vera
Meningitis C. neoformans Intolerance to 11 days
of AMB-d
180 Sterile CSF
day 11
Partial success
3 54 F None Pulmonary and
meningitis
C. gattii Primary therapy 181 Sterile CSF
day 14
Partial success
4 69 F Bladder CA Pulmonary C. neoformans Primary therapy 182 Presumed
eradication
Partial success
5 34 F None Pulmonary and
meningitis
C. gattii Primary therapy 176 Sterile CSF
day 165
Complete success
6 20 F None Pulmonary,
meningitis and
blood
C. gattii Refractory to 16 days of
AMB
181 Presumed
eradication
Partial success
7 66 M Heart transplant
pulmonary/
CNS
nocardiosis
Bone, skin and soft
tissue
C. neoformans Intolerance to 17 days
AMB
6 Presumed
persistence
Death – progression
(Day 7)
8 79 M NSCLC Pulmonary NOS Primary therapy 75 Presumed
eradication
Complete success
9 68 M Interstitial lung
disease
Meningitis C. neoformans Primary therapy 25 CSF sterile day 24 Stable failure
Abbreviations: AMB, amphotericin B; AMB-d, amphotericin B deoxcholate; CA, cancer; CNS, central nervous system; CSF, cerebrospinal fluid; DRC, data-review committee; EOT, end of
therapy; ISAV, isavuconazole; NOS, not otherwise specified (species identification not performed); NSCLC, non-small cell lung cancer.
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was seen in 24/38 (63%) of all patients at the end of therapy and
an overall 89% (34/38) survival rate. The majority of patients
treated in this study received ISAV as primary therapy and a suc-
cessful response was observed in patients with pulmonary,
non-CNS dissemination, and CNS infections. Although patient
numbers were small, this study found that both C. neoformans
and C. gattii responded similarly to ISAV, and this agent was suc-
cessfully used in the management of cryptococcal meningitis. In
patients refractory to or unable to tolerate prior antifungal ther-
apy, 60% (3/5) exhibited a successful response to ISAV suggesting
a potential role for this antifungal agent in the salvage setting as
well.
ISAV concentrations in the cerebrospinal fluid (CSF) and
brain have been evaluated in animal models and as compassion-
ate-use therapy during the Exserohilum fungal meningitis
outbreak [22]. Data from these patients showed CSF levels of
29–131 ng/mL with CSF/bloodstream ratios similar to those ob-
served with posaconazole and itraconazole [23, 24].Despite CSF
levels lower than those seen in the blood, efficacy in the treat-
ment of CNS infections has been observed in several murine
models of infection and brain/plasma ratios of 1.96 have been
found in a rat model, suggesting ISAV may be concentrated in
brain tissue [25]. Additionally, ISAV is equivalent to voriconazole
in the reduction of brain fungal burden during the treatment of
Candida infections [26], equivalent to L-AMB in a model of pul-
monary and CNS Rhizopus infection [11], and as effective as flu-
conazole in a model of cryptococcal meningitis [27]. Cumulatively,
these findings and our early results from human cryptococcal in-
fections suggest a potential role for ISAV in the treatment of CNS
mycoses.
The heterogeneity of these mycoses, including differences in
the host severity of illness, site of infection, concurrent medica-
tions, antifungal drug costs, and comorbidities plays a major
role in the selection of an antifungal agent for treatment. AMB
formulations are frequently prescribed for patients with severe
manifestations of endemic mycoses while fluconazole, itracona-
zole, posaconazole, or voriconazole are reserved for those with
mild-to-moderate disease or as “step-down” therapy following a
response or intolerance from induction AMB [1, 4–7]. Significant
differences do exist between the triazoles with regard to efficacy,
pharmacokinetics and pharmacodynamics, drug–drug interac-
tions, and toxicity [28] and balancing these concerns, particularly
for patients necessitating prolonged therapy, can be difficult.
Fluconazole, with limited potency, has a minor role in the treat-
ment of blastomycosis, paracoccidioidomycosis, and histoplasmo-
sis, and higher doses are frequently necessary for effectiveness
against coccidioidomycosis [5–8]. It is generally used in crypto-
coccosis during either low burden infections or in non-CNS infec-
tions. There are patient tolerability and absorption concerns with
itraconazole [9], and there are limited data on the efficacy of pos-
aconazole in the treatment of blastomycosis and paracoccidioido-
mycosis. Voriconazole has been demonstrated to be effective in
the treatment of these endemic fungi [29–31]. However, drug–
drug interactions and concerns with long-term use are common
during treatment [32, 33] and combined with limited clinical ex-
perience make this triazole an uncertain choice.
ISAV offers potential advantages over these agents. Lower
MICs have been described with ISAV compared to fluconazole
against a number of these pathogens [13]. Additionally, ISAV
can be taken with or without food [17], interpatient pharmacoki-
netic differences appear minimal [18], and fewer side-effects have
been found compared to voriconazole in a recently completed
phase 3 study of invasive aspergillosis [15]. Further evaluation
of ISAV in the treatment of these mycoses is needed, however,
the potential advantages over existing agents is encouraging and
this study supports further evaluation of this new triazole.
None of the patients reported here were discontinued from
the study drug primarily due to an AE. Thirty of the patients
received ISAV for >175 days suggesting long-term therapy,
which is often indicated in the treatment of these mycoses, is
tolerable.
The nonrandomized nature of this study limits the ability to
precisely compare the efficacy and safety of ISAV directly to
other triazoles used during treatment of these mycoses. Howev-
er, the response rate observed in this study is similar to those
previously reported for fluconazole, itraconazole, posaconazole,
and voriconazole in the treatment of endemic mycoses [30, 31,
34–38].The low number of patients enrolled with blastomycosis
also merits future evaluation in the treatment of this infection.
Other groups not included in this study, such as patients with
coccidioidal meningitis, sporotrichosis, and infection with Ta-
laromyces marneffei (formerly Penicillium marnefeii) could be
examined in future studies.
In summary, ISAV was effective in the treatment of this co-
hort of patients with cryptococcosis and dimorphic fungal in-
fections and the observed outcomes in these patients suggest
Table 4. Susceptibility of Endemic Fungi Infecting Patients With Primary
Disease, Refractory or Intolerant to Treatment per Clinical and Laboratory
Standards Institute Standards
Species
MIC Range (µg/mL)
ISAV VRC POS AMB
Cryptococcus spp.a
C. neoformans (n = 6) 0.008–0.12 0.03–0.25 0.03–0.25 0.06–1.0
C. gattii (n = 7) 0.008–0.12 0.03–0.06 0.03–0.12 0.5–1.0
Coccidioides immitis
(n = 6)
0.06–0.12 0.06–0.06 0.06–0.25 0.5–0.5
Histoplasma capsulatum
(n = 2)
0.03–0.03 0.06–0.25 0.06–0.12 0.12–0.12
Paracoccidioides
brasiliensis (n = 1)
0.001–0.001 0.03–0.03 0.03–0.03 0.25–0.25
Abbreviations: AMB, amphotericin B; ISAV, isavuconazole; MIC, minimum inhibitory
concentration; POS, posaconazole; VRC, voriconazole.
a Thirteen Cryptococcus isolates were collected from 9 patients. Blastomyces isolates were
not available for susceptibility testing.
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that it is a welcome addition to the limited antifungal armamen-
tarium for clinicians dealing with these mycoses.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
Notes
Acknowledgments. Study Group Members: We thank the investigators
(listed in Supplementary Material) and patients who participated in this
study.
Isavuconazole was co-developed by Astellas Pharma Global Develop-
ment, Inc. and Basilea Pharmaceutica International Ltd.
Independent Data and Safety Monitoring Board members were: Ben de
Pauw, MD, PhD, University Medical Centre, St Radboud, Nijmegen, The
Netherlands; John Wingard, MD, University of Florida, Gainesville, FL; and
Emmanuel Quinax, Independent Statistician. The Independent Data-Review
Committee members were: Oliver A. Cornely, MD, University of Cologne, Co-
logne, Germany; Luis Ostrosky-Zeichner, MD, University of Texas Medical
Center, Houston, TX; and John R. Perfect, MD, Duke University, Durham, NC.
The authors are grateful for the contributions of the investigators and
study center staff who conducted the studies, and the patients who partici-
pated in the VITAL trial.
Financial support. This study was funded by Astellas Pharma Global
Development, Inc. This work was supported by Astellas Pharma Global De-
velopment and Basilea Pharmaceutica International. They were involved in
study design, data collection, data analysis, data interpretation, and writing
of the report. All authors had full access to the study data and the corre-
sponding author had final responsibility for the decision to submit for
publication.
Potential conflicts of interest. G. R. T. has received grant support from
Astellas, Merck, and Wako. F. Q.-T. has received grant support for medical
education from Astellas, MSD, Pfizer, Teva, and United Medical, and for
research from Astellas, MSD, and Pfizer. L. O.-Z. has received grant support
and personal fees from Astellas and Pfizer, and personal fees from
Merck. N. A., R. M., M. L., and L. K. are full-time employees of Astellas
Pharma Global Development. M. E. is a full-time employee of Basilea Phar-
maceutica International Ltd. J. A. V. has received grant support, consulting
fees, and advisory board fees from Astellas. O. A. C. has received grants
and personal fees from Astellas, Gilead, Merck/MSD, Pfizer, Actelion,
Cubist/Optimer, Basilea, and Scynexis; grants from 3 M, Bayer, Celgene,
Genzyme, GSK, Miltenyi, Quintiles, AstraZeneca, Duke University (NIH
UM1AI104681), Leeds University, NanoMR, Novartis, Parexel, Virophar-
ma, and Roche; and personal fees from Da Volterra, Daiichi Sankyo, F2G,
Sanofi Pasteur, Summit, Vical, Vifor, Anacor, Cidara, Genentech, Matinas,
MedPace, Merck Serono, and Seres. J. R. P. has received grant support from
Astellas, Merck, Scynexis, and Cidara, and research or consulting fees from
Pfizer, F2G, Viamet, Vical, Arno, and Amplyx. All other authors report no
potential conflicts. All authors have submitted the ICMJE Form for Disclo-
sure of Potential Conflicts of Interest. Conflicts that the editors consider rel-
evant to the content of the manuscript have been disclosed.
References
1. Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotricho-
sis. Infect Dis Clin North Am 2006; 20:645–62.
2. Sabiiti W, May RC. Mechanisms of infection by the human fungal pathogen Cryp-
tococcus neoformans. Future Microbiol 2012; 7:1297–313.
3. Lortholary O, Denning DW, Dupont B. Endemic mycoses: a treatment update.
J Antimicrob Chemother 1999; 43:321–31.
4. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the
management of cryptococcal disease: 2010 update by the Infectious Diseases
Society of America. Clin Infect Dis 2010; 50:291–322.
5. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;
41:1217–23.
6. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the
management of blastomycosis: 2008 update by the Infectious Diseases Society of
America. Clin Infect Dis 2008; 46:1801–12.
7. Wheat LJ, Freifeld AG, KleimanMB, et al. Clinical practice guidelines for the man-
agement of patients with histoplasmosis: 2007 update by the Infectious Diseases
Society of America. Clin Infect Dis 2007; 45:807–25.
8. Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, Colombo AL, Moretti ML.
[Guidelines in paracoccidioidomycosis]. Rev Soc Bras Med Trop 2006; 39:297–310.
9. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: estab-
lished and emerging indications. Antimicrob Agents Chemother 2009; 53:24–34.
10. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) phar-
macodynamic target determination in an in vivo murine model of invasive pulmo-
nary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus
fumigatus. Antimicrob Agents Chemother 2013; 57:6284–9.
11. Luo G, Gebremariam T, Lee H, Edwards JE Jr, Kovanda L, Ibrahim AS. Isavuco-
nazole therapy protects immunosuppressed mice from mucormycosis. Antimi-
crob Agents Chemother 2014; 58:2450–3.
12. Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole phar-
macodynamic target determination for Candida species in an in vivo murine dis-
seminated candidiasis model. Antimicrob Agents Chemother 2013; 57:5642–8.
13. Thompson GR III, Wiederhold NP. Isavuconazole: a comprehensive review of
spectrum of activity of a new triazole. Mycopathologia 2010; 170:291–313.
14. Thompson GR III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patter-
son TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii
and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53:309–11.
15. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for pri-
mary treatment of invasive mould disease caused by Aspergillus and other filamen-
tous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Lancet 2016; 387:760–9.
16. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for
mucormycosis: open-label trial and contemporaneous case-control analysis. Lan-
cet Infect Dis 2016; doi:10.1016/S1473-3099(16)00071-2.
17. Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlan H, Yamazaki T, Townsend R.
Isavuconazole absorption following oral administration in healthy subjects is com-
parable to intravenous dosing, and is not affected by food, or drugs that alter stom-
ach pH. Int J Clin Pharmacol Ther 2016: In press.
18. Desai A, Kovanda L, Kowalski D, Lu Q, Townsend RW. Isavuconazole (ISA) pop-
ulation pharmacokinetic modeling from phase 1 and phase 3 clinical trials and
target attainment analysis. Washington, DC: Interscience Conference on Antimi-
crobial Agents and Chemotherapy (ICAAC), 5–9 September 2014. Poster A-697.
19. Isavuconazole [package insert]. Northbrook, IL: Astellas PharmaUS, Inc. revised 2015.
20. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal
disease from the European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of Aller-
gy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group. Clin Infect Dis 2008; 46:1813–21.
21. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts;
Approved Standard-Third Edition. CLSI document M27-A3. Wayne, PA: Clinical
and Laboratory Standards Institute.
22. Everson N, Smith J, Garner D. Successful treatment of contaminated epidural ste-
roid associated fungal meningitis with isavuconazole. Copenhagen, Denmark:
European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
25–28 April 2015. Poster P0231.
23. Wiederhold NP, Pennick GJ, Dorsey SA, et al. A reference laboratory experience of
clinically achievable voriconazole, posaconazole, and itraconazole concentrations
within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother
2014; 58:424–31.
24. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin
Drug Metab Toxicol 2007; 3:573–81.
25. Schmitt-Hoffmann AH, Richter WF. Isavuconazole is widely distributed in rat
tissue. London, UK: ECCMID, 31 March–3 April 2012. Poster P863.
26. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. Efficacy of isavucona-
zole, voriconazole and fluconazole in temporarily neutropenic murine models of
disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother
2009; 63:161–6.
27. Najvar LK, Wiederhold NP, Bocanegra R, Olivo M, Kirkpatrick WR, Patterson TF.
Isavuconazole is effective for the treatment of experimental cryptococcal menin-
gitis. ICAAC, 5–9 September 2014. Poster M-427.
28. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of system-
ic antifungal agents. Clin Infect Dis 2006; 43:S28–39.
29. Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections.
Antimicrob Agents Chemother 2009; 53:1648–51.
30. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A,
Shikanai-Yasuda MA. An open-label comparative pilot study of oral voriconazole
Isavuconazole – Endemic Fungal Infections • CID 2016:63 (1 August) • 361
and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect
Dis 2007; 45:1462–9.
31. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common,
emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122–31.
32. Moon WJ, Scheller EL, Suneja A, et al. Plasma fluoride level as a predictor of vor-
iconazole-induced periostitis in patients with skeletal pain. Clin Infect Dis 2014;
59:1237–45.
33. Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated
cutaneous malignancy: a literature review on photocarcinogenesis in organ trans-
plant recipients. Clin Infect Dis 2014; 58:997–1002.
34. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole
and itraconazole for progressive, nonmeningeal coccidioidomycosis. A
randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000;
133:676–86.
35. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccid-
ioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060–6.
36. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treat-
ment of central nervous system fungal infections. J Antimicrob Chemother 2005;
56:745–55.
37. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blasto-
mycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992;
93:489–97.
38. Naranjo MS, Trujillo M, Munera MI, Restrepo P, Gomez I, Restrepo A. Treatment
of paracoccidioidomycosis with itraconazole. J Med Vet Mycol 1990; 28:67–76.
362 • CID 2016:63 (1 August) • Thompson et al
